X4 Pharmaceuticals (XFOR) Upgraded to Buy: Heres What You Should Know
X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…
0,190$
1,60%
Echtzeit-Aktienkurs X4 Pharmaceuticals Inc
Bid:
Ask:
Nachrichten zur X4 Pharmaceuticals Inc Aktie
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
…
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +38.89% and +53.22%, respectively, for the quarter ended December 2025. Do…
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval
…
X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
…
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX)…
Craig Adam R buys x4 pharmaceuticals shares for $249,997 By Investing.com
Craig Adam R buys x4 pharmaceuticals shares for $249,997…
X4 Pharmaceuticals announces $145.6 million public offering of common stock By Investing.com
X4 Pharmaceuticals announces $145.6 million public offering of common stock…
X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the companys earnings…
X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript
…
X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript
…
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
…
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor)…
X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript
…
X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside
…
X4 Pharmaceuticals: PDUFA Excitement Ahead
…
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
…
X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript
…
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives…